Show simple item record

dc.contributor.authorKishida, Y.
dc.contributor.authorShingai, N.
dc.contributor.authorHara, K.
dc.contributor.authorYomota, M.
dc.contributor.authorKato, C.
dc.contributor.authorSakai, S.
dc.contributor.authorKambara, Y.
dc.contributor.authorAtsuta, Y.
dc.contributor.authorKonuma, R.
dc.contributor.authorWada, A.
dc.contributor.authorMurakami, D.
dc.contributor.authorNakashima, S.
dc.contributor.authorUchibori, Y.
dc.contributor.authorOnai, D.
dc.contributor.authorHamamura, A.
dc.contributor.authorNishijima, A.
dc.contributor.authorToya, T.
dc.contributor.authorShimizu, H.
dc.contributor.authorNajima, Y.
dc.contributor.authorKobayashi, T.
dc.contributor.authorSakamaki, H.
dc.contributor.authorOhashi, K.
dc.contributor.authorDoki, N.
dc.date.accessioned2022-10-07T01:08:18Z
dc.date.available2022-10-07T01:08:18Z
dc.date.issued2022
dc.identifier.citationKishida, Y., Shingai, N., Hara, K., Yomota, M., Kato, C., Sakai, S., Kambara, Y., Atsuta, Y., Konuma, R., Wada, A., Murakami, D., Nakashima, S., Uchibori, Y., Onai, D., Hamamura, A., Nishijima, A., Toya, T., Shimizu, H., Najima, Y., … Doki, N. (2022). Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation. Scientific Reports, 12(1).
dc.identifier.issn2045-2322
dc.identifier.pmid35986078
dc.identifier.doi10.1038/s41598-022-18553-6
dc.identifier.urihttp://hdl.handle.net/10150/666376
dc.description.abstractLate-onset noninfectious pulmonary complications (LONIPC) are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical impact of lung function deterioration itself in long-term adult survivors of HSCT remains to be fully investigated. This retrospective, longitudinal study aimed to investigate pulmonary function following HSCT in terms of its change and the clinical significance of its decline. We examined 167 patients who survived for at least 2 years without relapse. The median follow-up period was 10.3 years. A linear mixed-effects model showed that the slope of pulmonary function tests values, including percent vital capacity (%VC), percent forced expiratory volume in one second (%FEV1), and FEV1/forced VC ratio (FEV1%), decreased over time. The cumulative incidence of newly obstructive and restrictive lung function impairment (LFI) at 10 years was 15.7% and 19.5%, respectively. Restrictive LFI was a significant, independent risk factor for overall survival (hazard ratio 7.11, P = 0.007) and non-relapse mortality (hazard ratio 12.19, P = 0.003). Our data demonstrated that lung function declined over time after HSCT and that the decline itself had a significant impact on survival regardless of LONIPC. © 2022, The Author(s).
dc.language.isoen
dc.publisherNature Research
dc.rightsCopyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleImpact of lung function impairment after allogeneic hematopoietic stem cell transplantation
dc.typeArticle
dc.typetext
dc.contributor.departmentDepartment of Economics, University of Arizona
dc.identifier.journalScientific Reports
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleScientific Reports
refterms.dateFOA2022-10-07T01:08:18Z


Files in this item

Thumbnail
Name:
s41598-022-18553-6.pdf
Size:
1.195Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.